Coya net loss widens to $6.64 million in Q2 FY26; R&D expense rises to $5.03 million

Reuters2026/08/11 12:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Coya Therapeutics posted a GAAP net loss of $6.6 million, widening from a $6.1 million loss a year earlier; loss per share narrowed to $0.28 from $0.36.
GAAP operating loss widened to $7.05 million from $6.41 million as research and development expenses rose 35.8% to $5.03 million.
GAAP general and administrative expense fell 22.4% to $2.26 million; revenue rose to $243,745 from $163,616.
Cash and cash equivalents totaled $43.2 million at June 30, 2026, expected to fund operations into 2H 2027.
ALSTARS Phase 2 ALS trial advanced into a 24-week blinded extension; Fast Track designation granted for COYA 302, with ALS topline data targeted for Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coya Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260811698599) on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Coya net loss widens to $6.64 million in Q2 FY26; R&D expense rises to $5.03 million

You may also like

Crypto prices